EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients

Dandan Guan, Qingyang Shi, Yajuan Zheng, Chaopeng Zheng, Xuli Meng

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.04.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Dandan Guan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou Medical College of Soochow University, Soochow, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial Peopl…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Traditional Chinese Medicine Administration, National Natural Science Foundation of China, Department of Education of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyHumansFemaleMiddle AgedRetrospective StudiesAdultDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantAgedPrognosisReceptors, EstrogenChina

Stichwörter der Autor:innen

Breast cancerHER2-lowNeoadjuvant chemotherapyPathological responseReal-world data

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenERBB2 protein, human

Autor:innen und Institutionen

  • Suzhou Medical College of Soochow University, Soochow, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College,…
  • Department of Urinary Surgery, Haining branch of Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Jiaxing, Zhejiang, China.
  • General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China; Key Laboratory for diagnosis and t…
  • Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Förderung

  • Zhejiang Traditional Chinese Medicine Administration
  • National Natural Science Foundation of China
  • Department of Education of Zhejiang Province

Zitieren

APA

Guan, D., Shi, Q., Zheng, Y., Zheng, C., & Meng, X. (2024). Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.04.006

Vancouver

Guan D, Shi Q, Zheng Y, Zheng C, Meng X. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.04.006

BibTeX
@article{Guan2024,
  author = {Guan, Dandan and Shi, Qingyang and Zheng, Yajuan and Zheng, Chaopeng and Meng, Xuli},
  title = {Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.04.006}
}
Kostenlos starten →